化学療法誘発性血小板減少症（CIT）- 疫学予測 2028年
Chemotherapy-induced thrombocytopenia (CIT) - Epidemiology Forecast - 2028
|発行||DelveInsight Business Research LLP||商品コード||915398|
|出版日||ページ情報||英文 66 Pages
|化学療法誘発性血小板減少症（CIT）- 疫学予測 2028年 Chemotherapy-induced thrombocytopenia (CIT) - Epidemiology Forecast - 2028|
|出版日: 2019年11月01日||ページ情報: 英文 66 Pages||
DelveInsight's 'Chemotherapy-induced thrombocytopenia (CIT)-Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of Chemotherapy-induced thrombocytopenia in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Study Period: 2017-2028
Chemotherapy-induced thrombocytopenia - Disease Understanding
Thrombocytopenia can be defined as the deficiency of platelets (thrombocytes) that increase the risk of bleeding. Platelets maintain vascular endothelium integrity and control hemorrhage control following small-vessel injury by platelet plug formation and provide a firm, stable, fibrin clot in large injury. In Thrombocytopenia, the platelet count of patients drops down to less than 150 × 103 per µL.
The National Cancer Institute Common Toxicity Criteria defines Chemotherapy-induced thrombocytopenia (CIT) as a platelet count of fewer than 75,000 cells/µL, with the risk of bleeding, complications increase with lower platelet counts. However, there is no standard definition of CIT, it depends mostly on the observed platelet count reduction in clinical settings. It is a frequent complication associated with cancer therapy and the decrease in platelet count persists despite adequate recovery time from prior chemotherapy nadir, in the context of recovery of white cells and red cells.
The chemotherapy has improved the outcome of several cancers but is associated with various adverse effects (due to the cytotoxic nature), including hematological toxicities. The loss of platelets during chemotherapy called CIT is dose-limiting for chemotherapy treatment.
The Chemotherapy-induced thrombocytopenia epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the incident pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident cases of CIT and Total Incidence of CIT by Chemotherapeutic Agents) scenario of Chemotherapy-induced thrombocytopenia in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.
According to DelveInsight, the total Incident cases of Chemotherapy-induced thrombocytopenia (CIT) in the 7MM was found to be 302,735 in 2017. The incidence of Chemotherapy-induced thrombocytopenia in the 7MM is expected to increase during the study period of 2017-2028.
Among 7MM, the United States has the highest incident cases of Chemotherapy-induced thrombocytopenia with about 114,782 cases in 2017. Among EU-5 countries, Germany had the highest number of incident cases with approximately 35,594 cases, followed by France. Spain had the least number of incident cases, while in Japan, the incident cases of Chemotherapy-induced thrombocytopenia was found to be approximately 60,682.